NCT07197463Not yet recruiting
The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia
Study on the Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With Coronary Heart Disease Complicated by Sarcopenia:A Single Center, Randomized Control Study in China
Source: ClinicalTrials.gov · Last updated 29 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this clinical trial is to explore whether Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia. It will also investigate the mechanism of Phase I cardiac rehabilitation. The main questions it aims to answer are: * Can Phase I cardiac rehabilitation enhance muscle strength ? * Can Phase I cardiac rehabilitation reduce in vivo inflammatory indicators? Researchers will compare the experimental group (Phase I cardiac rehabilitation + drug therapy + general treatment) with the control group (drug therapy + general treatment) to see if Phase I cardiac rehabilitation can treat elderly patients with coronary heart disease complicated by sarcopenia and reduce inflammatory indicators. Participants will: * Receive Phase I cardiac rehabilitation training（mainly includes low-intensity resistance training, breathing training and bedside cycling） or conventional drug therapy for 3 consecutive months. * Undergo examinations 10 days after training, 1 month after discharge, and 3 months after discharge respectively. * Record changes in their muscle strength and blood inflammatory indicators.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 25 Jul 2025
- Start date
- 10 Oct 2025
- Primary completion date
- 10 Oct 2026
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Coronary artery disease
- NCT number
- NCT07197463
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 10 Oct 2025 to the primary completion date, 10 Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe arrhythmia, decompensated heart failure, severe respiratory failure, untreated severe aortic stenosis, acute aortic dissection, resting hypertension with systolic and/or diastolic blood pressure \> 200/110 mmHg;
- Mental disorders with limited cooperation ability; severe cognitive or behavioral disorders; end-stage diseases; acute diseases (e.g., acute infections, injuries) that restrict physical activity;
Other
- Poor compliance and inability to cooperate with the completion of this study.
Who the study is looking for
- Age ≥ 60 years;
- Coronary heart disease confirmed by coronary CTA or coronary angiography, with stable condition within the past 8 hours, including: ① no new or recurrent chest pain; ② no further elevation of troponin level; ③ no new signs of decompensated heart failure (dyspnea at rest accompanied by moist rales); ④ no new malignant arrhythmias or dynamic changes in electrocardiogram. Basic vital signs are normal, including: ① resting heart rate of 50-100 beats per minute; ② resting blood pressure of 90-150/60-100 mmHg (1 mmHg = 0.133 kPa); ③ oxygen saturation \> 95%.
- Meeting the diagnostic criteria for sarcopenia (2024 Edition of Chinese Guidelines for the Diagnosis and Treatment of Sarcopenia);
- Having good compliance to ensure the completion of this study;
- Being able to understand the purpose of the trial, voluntarily participating in the study and signing the informed consent form.
Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.